Okoye Afam A, Rohankhedkar Mukta, Konfe Audrie L, Abana Chike O, Reyes Matthew D, Clock Joseph A, Duell Derick M, Sylwester Andrew W, Sammader Partha, Legasse Alfred W, Park Byung S, Axthelm Michael K, Nikolich-Žugich Janko, Picker Louis J
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006; Oregon National Primate Research Center, Beaverton, OR 97006;
Bio5 Institute, University of Arizona, Tucson, AZ 85721;
J Immunol. 2015 Nov 1;195(9):4292-305. doi: 10.4049/jimmunol.1500609. Epub 2015 Sep 28.
Aging is associated with gradual deterioration of adaptive immune function, a hallmark of which is the profound loss of naive T cells (TN) associated with decline in thymic output and export of new cells into the peripheral T cell pool. Because the lymphotropic cytokine IL-7 plays crucial roles in both development of TN in the thymus and TN homeostasis in the periphery, we sought to determine the extent to which therapeutic administration of IL-7 could reverse TN deficiency in aging rhesus macaques (RM), either by enhancement of the demonstrably reduced thymopoiesis or by peripheral TN expansion. Our results indicate that treatment of both adult (8-15 y) and old (>20 y) RM with recombinant simian IL-7 (rsIL-7) results in only transient increases in peripheral CD4(+) and CD8(+) TN numbers with no long-term benefit, even with repeated therapy. This transient effect was due to peripheral TN expansion and not enhanced thymic function, and appeared to be limited by induction of IL-7 nonresponsiveness. However, rsIL-7 therapy had a more promising effect on the central memory T cell (TCM) population (both CD4(+) and CD8(+)) in adult and old RM, doubling the numbers of these cells in circulation and maintaining this larger population long term. IL-7 therapy did not reduce TCR diversity of the memory T cell compartment, suggesting that rsIL-7-induced expansion was symmetrical. Thus, although rsIL-7 failed to counter age-associated TN loss, the ability of this therapy to expand clonotypically diverse CD4(+) and CD8(+) TCM populations might potentially improve adaptive immune responsiveness in the elderly.
衰老与适应性免疫功能的逐渐衰退有关,其一个标志是初始T细胞(TN)的大量丧失,这与胸腺输出减少以及新细胞进入外周T细胞库的数量下降有关。由于亲淋巴细胞细胞因子IL-7在胸腺中TN的发育以及外周TN的稳态维持中均发挥关键作用,我们试图确定通过增强明显减少的胸腺生成或通过外周TN扩增,IL-7的治疗性给药在多大程度上能够逆转衰老恒河猴(RM)的TN缺陷。我们的结果表明,用重组猴IL-7(rsIL-7)治疗成年(8 - 15岁)和老年(>20岁)RM,仅导致外周CD4(+)和CD8(+) TN数量短暂增加,即使重复治疗也没有长期益处。这种短暂效应是由于外周TN扩增而非胸腺功能增强所致,并且似乎受IL-7无反应性诱导的限制。然而,rsIL-7治疗对成年和老年RM的中央记忆T细胞(TCM)群体(CD4(+)和CD8(+))有更有前景的效果,使循环中这些细胞的数量翻倍并长期维持这一较大群体。IL-7治疗并未降低记忆T细胞区室的TCR多样性,表明rsIL-7诱导的扩增是对称的。因此,尽管rsIL-7未能对抗与年龄相关的TN丧失,但该疗法扩增克隆型多样的CD4(+)和CD8(+) TCM群体的能力可能会潜在地改善老年人的适应性免疫反应性。